These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1609046)

  • 1. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.
    Chakos MH; Mayerhoff DI; Loebel AD; Alvir JM; Lieberman JA
    Psychopharmacol Bull; 1992; 28(1):81-6. PubMed ID: 1609046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of clozapine response in schizophrenia.
    Pickar D; Owen RR; Litman RE; Hsiao JK; Su TP
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():129-32. PubMed ID: 7525541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of extrapyramidal symptoms during acute neuroleptic treatment.
    Mazure CM; Cellar JS; Bowers MB; Nelson JC; Takeshita J; Zigun B
    J Clin Psychiatry; 1995 Mar; 56(3):94-100. PubMed ID: 7883736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Course of psychopathologic and extrapyramidal motor symptoms during long-term treatment of schizophrenic patients with psycholeptic drugs (author's transl)].
    Schilkrut R; Duran E; Haverbeck C; Katz I; Vidal P
    Arzneimittelforschung; 1978; 28(9):1494-5. PubMed ID: 38807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients.
    Koreen AR; Lieberman J; Alvir J; Chakos M; Loebel A; Cooper T; Kane J
    Am J Psychiatry; 1994 Jan; 151(1):35-9. PubMed ID: 8267132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.
    Zhornitsky S; Stip E; Pampoulova T; Rizkallah E; Lipp O; Bentaleb LA; Chiasson JP; Potvin S
    Mov Disord; 2010 Oct; 25(13):2188-94. PubMed ID: 20669315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.
    Rybakowski JK; Vansteelandt K; Remlinger-Molenda A; Fleischhacker WW; Kahn RS; Peuskens J;
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1500-5. PubMed ID: 25085534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
    Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
    Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-episode schizophrenia: the importance of early intervention and subjective tolerability.
    Kasper S
    J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
    Wynchank D; Berk M
    Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute neuroleptic-induced movement disorders.
    Tonda ME; Guthrie SK
    Pharmacotherapy; 1994; 14(5):543-60. PubMed ID: 7997388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian agents and fluphenazine decanoate.
    Idzorek S
    Am J Psychiatry; 1976 Jan; 133(1):80-2. PubMed ID: 1247126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.